Eversheds Sutherland advises Edwards Lifesciences on its US$4.2bn sale of Critical Care
September 06, 2024
Eversheds Sutherland advises Edwards Lifesciences on its US$4.2bn sale of Critical CareSeptember 06, 2024 Eversheds Sutherland has advised Edwards Lifesciences on the US$4.2bn sale of its Critical Care product group to Becton, Dickinson and Company (BD). Edwards Lifesciences is a global leader in patient-focused medical innovations for structural heart disease. The Critical Care product group is an industry leader in advanced patient monitoring with advanced AI algorithms serving millions of patients globally. Key contacts
Lee Harris Partner United Kingdom Antony Walsh Partner United Kingdom Barri Mendelsohn Partner United Kingdom Rachel Cooper Partner United Kingdom Edward M. Tompkin-Haag Partner United Kingdom Kelly Holmes Partner United Kingdom Philip Crosbie Partner United Kingdom Christopher Murray Partner United Kingdom Latest Insights
Latest News
Latest Eventslegal updates June 03, 2026 Global Life Sciences & Healthcare Bulletin legal updates June 02, 2026 Georgia’s corporate governance reform: Key changes under HB 1185 legal updates June 02, 2026 Illinois tax increases part two: Digital asset privilege tax, prediction ma... legal updates June 01, 2026 Illinois tax increases part one: Digital services taxes client news June 03, 2026 A blueprint for growth: Eversheds Sutherland supports Leonard Design Group ... client news June 02, 2026 Next stop, public ownership: Eversheds Sutherland advises DfT on GTR transi... firm news June 01, 2026 Eversheds Sutherland strengthens restructuring offering with senior partner... firm news June 01, 2026 Eversheds Sutherland strengthens Commercial Advisory practice with technolo... |